Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. 4SC AG
  6. Summary
    VSC   DE000A14KL72

4SC AG

(VSC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
1.97 1.99 2.04 1.97 1.99 Last
160 20 0 0 0 Volume
0.00% +1.02% +2.51% -3.43% +1.02% Change
Estimated financial data (e)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Sales 2021 14,0 M 14,8 M 14,8 M
Net income 2021 -10,2 M -10,7 M -10,7 M
Net cash position 2021 29,4 M 31,0 M 31,0 M
P/E ratio 2021 -3,61x
Yield 2021 -
Capitalization 20,1 M 21,2 M 21,2 M
EV / Sales 2020
EV / Sales 2021 0,54x
Nbr of Employees 46
Free-Float 26,0%
More Financials
Company
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the... 
Read more
More about the company
All news about 4SC AG
05/054SC AG Announces Resminostat and RESMAIN Study Update
CI
03/224SC AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/224SC AG Auditor Raises 'Going Concern' Doubt
CI
20214Sc Ag Announces Netherlands Cancer Institute Enrolls First Patient Enrolled in Turando..
CI
2021TRANSCRIPT : 4SC AG, H1 2021 Earnings Call, Aug 10, 2021
CI
20214SC AG : REVERSE SPLIT: 1 of 5
FA
20214SC Initiates Second Clinical Collaboration with the Netherlands Cancer Institute
CI
2021TRANSCRIPT : 4SC AG, Q1 2021 Earnings Call, Apr 20, 2021
CI
2021SECTOR UPDATE : Health Care Stocks Nursing Moderate Gains
MT
2021IMMUNIC : 4SC AG Sign IMU-838 Settlement Deal
MT
20214SC AG Provides Earnings Guidance for 2021
CI
20214SC AG Auditor Raises 'Going Concern' Doubt
CI
20204SC AG Announces Positive Safety Review of Phase Ib/II EMERGE Study of domatinostat + a..
CI
20204Sc Ag Reports Earnings Results for the Second Quarter Ended June 30, 2020
CI
2020TRANSCRIPT : 4SC AG, Q2 2020 Earnings Call, Aug 11, 2020
CI
More news
News in other languages on 4SC AG
05/054SC AG annonce la mise à jour de l'étude Resminostat et RESMAIN
03/224SC AG annonce ses résultats pour l'année complète se terminant le 31 décembre 2021
03/22L'auditeur de 4SC AG soulève des doutes sur la continuité de l'exploitation
2021NACHBÖRSE/XDAX +0,1% auf 15.803 Punkte - Qiagen leichter
2021MISE À JOUR SECTORIELLE : Les actions du secteur de la santé affichent des gains modérés
More news
Chart 4SC AG
Duration : Period :
4SC AG Technical Analysis Chart | VSC | DE000A14KL72 | MarketScreener
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 1,99
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jason Loveridge Chief Executive Officer
Clemens M. Doppler Member-Supervisory Board
Susanne Danhauser-Riedl Chief Medical Officer
Manfred Rüdiger Member-Supervisory Board
Helmut Jeggle Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
4SC AG-45.48%21
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612